European Vaccine Initiative, UniversitätsKlinikum Heidelberg, Im Neuenheimer Feld 326-3. OG, 69120 Heidelberg, Germany.
Expert Rev Vaccines. 2011 Dec;10(12):1697-708. doi: 10.1586/erv.11.158.
For over 10 years, the European Vaccine Initiative (EVI; European Malaria Vaccine Initiative until 2009) has contributed to the development of 24 malaria candidate vaccine antigens with 13 vaccine candidates being advanced into Phase I clinical trials, two of which have been transitioned for further clinical development in sub-Saharan Africa. Since its inception the EVI organization has operated as a funding agency, but with a clear service-oriented strategy. The scientific successes and difficulties encountered during these years and how these efforts have led to standardization and harmonization in vaccine development through large-scale European consortia are discussed. In the future, the EVI will remain instrumental in the pharmaceutical and clinical development of vaccines against 'diseases of poverty' with a continued focus on malaria. EVI will continue to focus on funding and managing preclinical evaluation up to Phase I/II clinical trials and strengthening the vaccine-development infrastructure in Europe, albeit with a global orientation.
10 多年来，欧洲疫苗倡议（EVI；2009 年前称为欧洲疟疾疫苗倡议）一直致力于开发 24 种疟疾候选疫苗抗原，其中 13 种疫苗候选物已进入 I 期临床试验，其中两种已在撒哈拉以南非洲地区进一步临床开发中转移。自成立以来，EVI 组织一直作为一个资助机构运作，但具有明确的以服务为导向的战略。本文讨论了这些年来的科学成功和遇到的困难，以及这些努力如何通过大规模的欧洲联盟导致疫苗开发的标准化和协调。未来，EVI 将继续在“贫困病”药物和临床疫苗开发方面发挥重要作用，继续关注疟疾。EVI 将继续专注于资助和管理 I/II 期临床试验前评估，并加强欧洲的疫苗开发基础设施，尽管具有全球定位。
